Immunotherapy change overcomes acquired resistance after chemo-immunotherapy in unresectable biliary tract cancer
Changing immunotherapy regimen is a promising strategy for overcoming AR to first-line immunotherapy-chemotherapy combination in uBTC, while adjusting targeted therapy and adding LRT may help overcome PR.
Authors
- Shuofeng Li (ORCID: https://orcid.org/0000-0002-6033-6476)
- Guanhua Yu
- Chengjie Li (ORCID: https://orcid.org/0000-0001-5602-6566)
- Boyu Sun
- Zixiang Zhou (ORCID: https://orcid.org/0009-0002-4643-7331)
- Kai Liu (ORCID: https://orcid.org/0000-0002-4152-1975)
- Ze Zhou (ORCID: https://orcid.org/0000-0002-7265-7541)
- Xiangqi Chen (ORCID: https://orcid.org/0000-0003-3367-6261)
- Haitao Zhao (ORCID: https://orcid.org/0000-0002-3444-8044)
- Zhenyu Zhu
- Mingming Wang (ORCID: https://orcid.org/0009-0005-9972-5056)
- Shanshan Wang (ORCID: https://orcid.org/0000-0002-1281-2343)
- Li Hu (ORCID: https://orcid.org/0000-0002-6657-4707)
- Feng Shi (ORCID: https://orcid.org/0000-0002-1850-7796)
- Yihong Zhang (ORCID: https://orcid.org/0000-0003-1261-1661)
- Chengpei Zhu
- Mingjian Piao (ORCID: https://orcid.org/0009-0005-4981-5942)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- Chinese PLA General Hospital (CN)
- Beijing YouAn Hospital (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1007/s00262-025-04181-2
- Citations
- 1
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.01